English, Article edition: Tapering Off Benzodiazepines in Long-Term Users: An Economic Evaluation Richard C. Oude Voshaar; Paul F.M. Krabbe; Wim J.M.J. Gorgels; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/95174
Physical Description
  • article
Language
  • English

Edition details

Title
  • Tapering Off Benzodiazepines in Long-Term Users: An Economic Evaluation
Author
  • Richard C. Oude Voshaar
  • Paul F.M. Krabbe
  • Wim J.M.J. Gorgels
  • Eddy M.M. Adang
  • Anton J.L.M. van Balkom
  • Eloy H. van de Lisdonk
  • Frans G. Zitman
Physical Description
  • article
Notes
  • Background: Discontinuation of benzodiazepine usage has never been evaluated in economic terms. This study aimed to compare the relative costs and outcomes of tapering off long-term benzodiazepine use combined with group cognitive behavioural therapy (TO+CBT), tapering off alone (TOA) and usual care. Method: A randomised controlled trial was conducted, incorporating a cost-effectiveness analysis from a societal as well as a pharmaceutical perspective. The cost of intervention treatment, prescribed drugs, healthcare services, productivity loss, and patients' costs were measured using drug prescription data and cost diaries. Costs were indexed at 2001 prices. The principal outcome was the proportion of patients able to discontinue benzodiazepine use during the 18-month follow-up. A secondary outcome measure was quality of life (Health Utility Index Mark III [HUI-3] and the Medical Outcomes Study 36-item Short-Form Health Survey [SF-36]). Results: A total of 180 patients were randomised to one of TO+CBT (n =​ 73), TOA (n =​ 73) or usual care (n =​ 34). Intervention treatment costs were an average of _172.99 per patient for TO+CBT and _69.50 per patient for TOA. Both treatment conditions significantly reduced benzodiazepine costs during follow-up compared with usual care. The incremental cost-effectiveness ratios (ICERs) showed that, for each incremental 1% successful benzodiazepine discontinuation, TO+CBT cost _10.30-62.53 versus usual care, depending on the study perspective. However, TO+CBT was extendedly dominated or was dominated by TOA. This resulted in ICERs of _0.57, _10.21 and _48.92 for TOA versus usual care from the limited pharmaceutical, comprehensive pharmaceutical and societal perspective, respectively. Conclusions: TO+CBT and TOA both led to a reduction in benzodiazepine costs. However, it remains uncertain which healthcare utilisation has a causal relationship with long-term benzodiazepine consumption or its treatment. Although the ICERs indicated better cost effectiveness for TOA than for TO+CBT, the differences were relatively small. The addition of group CBT to tapering off had no clinical or economic advantages. Extrapolation of our data showed that the investment in TOA was paid back after 19 months when corrected for treatment gain with usual care.
  • Anxiety-disorders, Benzodiazepines, Cognitive-behavioural-therapy, Cost-effectiveness, Drug-withdrawal, Quality-of-life, Randomised-controlled-trials
  • RePEc:wkh:phecon:v:24:y:2006:i:7:p:683-694
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment